英夫力西单抗与硫唑嘌呤治疗难治性炎症性肠病的效果对比

Comparison of efficacy of infliximab and azathioprine in the treatment of refractory inflammatory bowel disease

目的:比较用英夫力西单抗与硫唑嘌呤治疗难治性炎症性肠病的临床效果。方法:选择2018年5月至2019年5月解放军联勤保障部队第九二四医院消化内科接诊的80例难治性炎症性肠病患者为研究对象。采用随机数表法将其分为英夫力西单抗(Infliximab,IFX)组和硫唑嘌呤(Azathioprine,AZA)组,每组各40例患者。为IFX组患者和AZA组患者分别采用IFX与AZA进行治疗,然后对比两组患者肠道黏膜的愈合率、Mayo评分和UC内镜评分。结果:治疗后,两组患者肠道黏膜的愈合率、Mayo评分、UC内镜评分相比,P>0.05。结论:用IFX与AZA治疗难治性炎症性肠病的临床疗效相当。

Objective:To compare the clinical effects of infliximab and azathioprine in the treatment of refractory inflammatory bowel disease.METHODS:A total of 80 patients with refractory inflammatory bowel disease admitted to the Department of Gastroenterology,No.924 Hospital of PLA Joint Logistic Support Force from May 2018 to May 2019 were selected as the research subjects.The patients were divided into Infliximab(IFX)group and Azathioprine(AZA)group by random number table method,with 40 patients in each group.Patients in the IFX group and the AZA group were treated with IFX and AZA,respectively,and then intestinal mucosal healing rate,Mayo score and UC endoscopic score were compared between the two groups.Results:After treatment,the healing rate of intestinal mucosa,Mayo score and UC endoscopic score in 2 groups were compared with P>0.05.Conclusion:The clinical efficacy of IFX and AZA in the treatment of refractory inflammatory bowel disease is comparable.